Dostarlimab

Generic Name
Dostarlimab
Brand Names
Jemperli
Drug Type
Biotech
Chemical Formula
-
CAS Number
2022215-59-2
Unique Ingredient Identifier
P0GVQ9A4S5
Background

Dostarlimab is an IgG humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically att...

Indication

Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.
...

Associated Conditions
Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer, Advanced Mismatch repair deficient (dMMR) solid tumors, Recurrent Microsatellite Instability (MSI)-High Endometrial Cancer, Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer, Recurrent Mismatch repair deficient (dMMR) solid tumors
Associated Therapies
-
Clinical Trials
Related News

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

First Posted Date
2021-05-20
Last Posted Date
2022-06-29
Lead Sponsor
Walid Shaib, MD
Registration Number
NCT04895046

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

First Posted Date
2021-04-08
Last Posted Date
2023-11-15
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
32
Registration Number
NCT04837209
Locations
🇺🇸

Sibley Memorial Hospital, Washington, District of Columbia, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

First Posted Date
2021-03-03
Last Posted Date
2024-03-26
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
51
Registration Number
NCT04779151
Locations
🇫🇷

Gustave Roussy, Villejuif, Val De Marne, France

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

First Posted Date
2021-03-01
Last Posted Date
2024-11-11
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
62
Registration Number
NCT04774419
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (All Protocol Activites), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

First Posted Date
2021-01-08
Last Posted Date
2024-10-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
48
Registration Number
NCT04701307
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

First Posted Date
2020-12-22
Last Posted Date
2021-08-27
Lead Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Target Recruit Count
427
Registration Number
NCT04679064
Locations
🇮🇹

Istituto Tumori della Romagna IRST IRCCS, Meldola, Italy

🇮🇹

Azienda Ospedaliera Spedali Civili, Brescia, Italy

🇮🇹

IEO-Istituto Europeo di Oncologia, Milan, Italy

and more 5 locations

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

First Posted Date
2020-12-17
Last Posted Date
2024-11-08
Lead Sponsor
University of Washington
Target Recruit Count
18
Registration Number
NCT04673448
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

First Posted Date
2020-12-07
Last Posted Date
2024-11-05
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
758
Registration Number
NCT04655976
Locations
🇬🇧

GSK Investigational Site, Manchester, United Kingdom

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

First Posted Date
2020-10-12
Last Posted Date
2024-05-29
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
62
Registration Number
NCT04584255
Locations
🇺🇸

Yale University Cancer Center, New Haven, Connecticut, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 6 locations

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

First Posted Date
2020-10-09
Last Posted Date
2024-12-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
243
Registration Number
NCT04581824
Locations
🇨🇳

GSK Investigational Site, Taipei, Taiwan

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy